liberDi featured in BioTuesdays

liberDi readies first-in-man study of portable dialysis system

By Leonard Zehr, BioTuesdays

liberDi's Hezkiah Tsoory

liberDi CEO Hezkiah Tsoory

Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed to improve patient’s quality of life, and reduce treatment costs and complications.

“Patients with end-stage renal disease (ESRD) mostly travel to a dialysis center three times a week for a typically three- to five-hour procedure, while our system can complete fluid exchange in approximately 20 minutes at home, at the office or while traveling,” founder and CEO, Hezkiah Tsoory, says in an interview with BioTuesdays.

“The low utilization of home dialysis is a lost opportunity to improve patient’s quality of life and decrease healthcare costs,” he adds, quoting from a journal article published last year.


According to Mr. Tsoory, only 11% of patients worldwide receive peritoneal dialysis at home because existing devices have significant limitations for patients and physicians, as well as a risk of peritonitis, an inflammation of the peritoneum that lines the inner wall of the abdomen and covers and supports most abdominal organs.

Read the full article on BioTuesdays.